Tislelizumab


Tislelizumab is a humanized monoclonal antibody directed against PD-1. It prevents PD-1 from binding to the ligands PD-L1 and PD-L2. It is being investigated as a treatment for advanced solid tumors.
It is designed to bind less to Fc gamma receptors.
It is being developed by BeiGene.

Medical Uses

China

Tislelizumab was approved by the China National Medical Products Administration :
Phase I trials began in the US and Australia in June 2015 and were expected to complete in mid-2017. Some early results were announced in July 2016.
A pivotal phase 2 clinical trial for urothelial cancer started in China in 2017.
It is in a phase 3 trial for NSCLC.
A multicenter phase 3 trial for advanced hepatocellular carcinoma started in Jan 2018.

Pharmacokinetics

Early phase I clinical trial results give an elimination half-life of 11 to 17 days.